1. Home
  2. FTNT vs VRTX Comparison

FTNT vs VRTX Comparison

Compare FTNT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortinet Inc.

FTNT

Fortinet Inc.

N/A

Current Price

$153.01

Market Cap

113.6B

Sector

Technology

ML Signal

N/A

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$554.23

Market Cap

123.4B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
FTNT
VRTX
Founded
2000
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
113.6B
123.4B
IPO Year
2009
2006

Fundamental Metrics

Financial Performance
Metric
FTNT
VRTX
Price
$153.01
$554.23
Analyst Decision
Hold
Buy
Analyst Count
25
29
Target Price
$85.71
$539.69
AVG Volume (30 Days)
4.9M
1.2M
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
7.08
836.54
EPS
1.54
8.33
Revenue
$6,799,600,000.00
$2,488,652,000.00
Revenue This Year
$14.02
$10.79
Revenue Next Year
$10.51
$10.47
P/E Ratio
$98.69
$65.74
Revenue Growth
14.17
46.20
52 Week Low
$73.55
$374.17
52 Week High
$172.09
$555.32

Technical Indicators

Market Signals
Indicator
FTNT
VRTX
Relative Strength Index (RSI) 43.84 67.74
Support Level $152.25 $458.05
Resistance Level $171.22 N/A
Average True Range (ATR) 5.03 13.77
MACD -1.38 3.82
Stochastic Oscillator 22.33 93.74

Price Performance

Historical Comparison
FTNT
VRTX

About FTNT Fortinet Inc.

Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: